explore -WSS

explore

author：leisure time 2025-09-30 17:29:13 - browse：4

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： The problem with charging patients to message their doctors

Wikipedia

WSS

2024 GOP presidential candidates spar over abortion in debate

Sen. Paul opposes bill to ban Chinese biotechs

Appeals court upholds limits to abortion pill

FDA panel gives mixed vote on blood pressure devices

Just how do doctors, lawmakers, and the public define abortion?

Just how do doctors, lawmakers, and the public define abortion?

entertainment

explore

focus

Jerome Adams on the need for new antivirals for Covid

AstraZeneca challenges Medicare drug negotiation program

After affirmative action ruling, medical educators look to 'holistic review'

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Hepatitis C has a cure — but many Americans still lack access to it

Medicare explains how it will choose drugs for negotiation

Drug repurposing or repositioning? The language matters

Radiation, mainstay of cancer treatment, begins a fade

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Appeals court upholds limits to abortion pill

explore

What AAP's gender

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Just how do doctors, lawmakers, and the public define abortion?

How to make AI work for medicine

In his State of the Union, Biden takes clear aim at 'Big Pharma'

What AAP's gender

hotspot

Wikipedia

entertainment

explore